NCT00434226View on ClinicalTrials.gov

A Study of Sunitinib in Combination With Bevacizumab, Carboplatin, and Paclitaxel in Patients With Advanced Non-Small Cell Lung Cancer (SABRE-L)

PHASE2TerminatedINTERVENTIONAL
Enrollment

56

Participants

Timeline

Start Date

March 31, 2007

Primary Completion Date

April 30, 2008

Conditions
Non-Small Cell Lung Cancer
Interventions
DRUG

bevacizumab

Intravenously at a dose of 15mg/kg on the first day of each 21-day cycle

DRUG

sunitinib

25 mg/day for 2 weeks, followed by 1 week of rest

DRUG

carboplatin

On the first day of each cycle for 4 cycles

DRUG

paclitaxel

On the first day of each cycle for 4 cycles

Sponsors

Lead Sponsor

Genentech, Inc.
All Listed Sponsors
lead

Genentech, Inc.

INDUSTRY